Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FibroCAN
2024-516597-30-00Phase 2Authorised
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic cardiac autonomic neuropathy (CAN) comparing Finerenone with Placebo (2 arms). Primary endpoint: CART E/I ratio. Planned start Nov 2024; status: authorised.
02
Drugs
finerenone
03
Conditions
diabetic cardiac autonomic neuropathy (CAN)
Beyond the preview
Go deeper on 2024-516597-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516597-30-00.